clinical_trials
Oral LSD Drug Hits Phase III Endpoints in Anxiety, Depression
Confidence86·multiple reportsImportance88NP-EVT-20261107-D8F902F
(MedPage Today) -- DT120, an investigational orally disintegrating tablet (ODT) formulation of the psychedelic lysergide (LSD), met the primary endpoints in a pair of phase III trials for generalized anxiety disorder (GAD) and major depressive...
Read the original at the primary source
Oral LSD Drug Hits Phase III Endpoints in Anxiety, Depression
11/7/2026, 9:46:40 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —